AMGN Amgen Inc
Company Analysis
Latest News
Amgen’s Repatha reduces death risk 20%, first for primary prevention patients
Amgen reported that its cholesterol drug Repatha (evolocumab) reduced all-cause death risk by 20% in high-risk adults. The Phase 3 VESALIUS-CV trial focused on...
Amgen and AstraZeneca Report Positive Phase 3 Tezspire Data for Esophageal Disorder
Amgen and AstraZeneca announced positive top-line results from the Phase 3 CROSSING trial for Tezspire. The drug treats eosinophilic esophagitis (EoE). EoE is...
🟢 Amgen is trading 3.17% up today on broad biotech rally
Amgen is trading 3.17% up at $438.76 as biotechnology shares rally broadly on positive Moderna-Merck Phase 3 melanoma vaccine results. - The sector ETF XBI is...
Amgen Tops $10 Billion in Quarterly Revenue and Raises Its 2026 Outlook — But Can a $57 Billion Debt Load Coexist With Growth?
Shares surged 4.2% to $406.39 after Amgen posted second-quarter results that blew past Wall Street expectations on every major line, then raised full-year...
🟢 Amgen is trading 4.2% up today after Q2 earnings beat and raised 2026 outlook
Amgen is trading 4.2% up now at $406.39 after reporting better-than-expected second-quarter results and raising its 2026 outlook. • Revenue grew 10%...
Amgen's second quarter revenue of $10.1B and EPS of $6.29 beat estimates, driven by strong growth in key products.
Amgen reported second quarter 2026 total revenues of $10.1 billion, a 10% year-over-year increase, with non-GAAP earnings per share rising 4% to $6.29. The...
🟢 Amgen is trading 3.2% up today ahead of Q2 earnings and MariTide updates
Amgen is trading 3.2% up at $397.61 in pre-market action ahead of its second-quarter 2026 earnings report scheduled for August 04. • The move reflects...
Amgen Inc Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026
Amgen is expected to report consensus revenue of $9.08 billion and adjusted EPS of $5.60 for the second quarter, as the stock trades at $335.50 relative to a...
Amgen Suffers Cloud Data Breach, Hackers Steal Patient Health Information
Amgen disclosed a significant cybersecurity breach on July 31, 2026. Hackers gained unauthorized access to data stored in third-party cloud environments. The...
Amgen wins EU backing for Repatha, targeting first-time heart attacks
Amgen received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) to expand Repatha’s label. The recommendation supports...
🟢 Amgen is trading 3.5% up today amid a broader biotech sector rally
Amgen is trading 3.5% up today at $389.50 as the stock benefits from a broader rally across the biotech sector, outperforming a mixed market backdrop. • There...
Amgen fights FDA withdrawal of Tavneos, citing new trial data
Amgen formally submitted new data and analyses to the U.S. Food and Drug Administration (FDA) on July 23, 2026. The company announced the filing on July 24 to...
🔴 Amgen is trading 6.3% down today amid broad market weakness and thin after-hours liquidity
Amgen is trading at $348.22 (6.3% down) in after-hours trading, moving lower alongside a broader market retreat. • The stock saw a sharp decline from its...
🔴 Amgen is trading 20.3% down today following a sharp after-hours selloff with no clear catalyst
Amgen is trading at $291.77 (-20.34%) in after-hours trading following a sharp selloff that appears unexplained by current news flow. • The stock plummeted...
Amgen Advances Key Obesity Drug with Positive Data on Injection Formats
Amgen completed a Phase 1 clinical trial for its obesity drug candidate, MariTide (maridebart cafraglutide or AMG 133). The study evaluated how the drug...
🔴 Amgen is trading 4.24% down today following UK funding cut recommendation for Lumykras
Amgen's lung cancer drug Lumykras will no longer be funded for new patients in England and Wales, following a recommendation from the National Institute for...
Amgen Blocks Colorado Price Cap on Enbrel, Stalling State Cost Controls
Chief Judge Daniel Domenico of the Denver federal court granted Amgen a preliminary injunction on Wednesday. The ruling blocks Colorado from implementing a...
Amgen’s Tavneos Faces EU Ban, Citing Misleading Clinical Data
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended revoking the marketing authorization for Amgen’s...
Amgen Upgraded to Buy, Boosted by Obesity and Eye-Disease Drug Trials
Wall Street Zen upgraded Amgen Inc. (NASDAQ:AMGN) from hold to buy on June 14, 2026. The stock maintains a consensus hold rating with an average price target...
Amgen's first quarter 2026 revenue grew 6% as strong performance from key growth products offset biosimilar pressures.
Amgen reported first quarter 2026 revenues of $8.6 billion, a 6% year-over-year increase, and non-GAAP EPS of $5.15, up 5% from the prior year. The results...